Mirum will present longer-term hepatitis D response data, including in people with cirrhosis.
Mirum Pharmaceuticals will present data on its hepatitis D treatment, brelovitug, at The Liver Meeting 2026, including Phase 3 results and longer-term efficacy in patients with cirrhosis. The company will also share additional analyses on volixibat for primary sclerosing cholangitis (PSC) and new evidence on LIVMARLI (maralixibat) for rare cholestatic liver diseases.
How this was made
The 30-second read
Why it matters
The disclosed data could be a catalyst for price movement and affect peer valuations.
Market read
First public release of Phase 3 hepatitis D data; potential catalyst for biotech sector.
What to watch
Regulatory pathway and reimbursement uncertainties could temper upside.
Background
Mirum Pharmaceuticals (NASDAQ: MIRM) focuses on rare liver diseases; upcoming data from its Phase 3 AZURE-1 trial is highly anticipated.
Ticker impact
Mirum Pharmaceuticals will present new Phase 3 AZURE-1 hepatitis D data and longer-term results, including in cirrhosis patients, at The Liver Meeting 2026.
likely upward pressure as market prices in the new efficacy data
First disclosure of late-breaking Phase 3 results, a material catalyst for a biotech.
Market effects
May lift sentiment for hepatitis D and rare liver disease therapeutics sector.
US biotech investors likely to react; limited regional effect.
Limited to global biotech community.
Counterpoint
If data shows only modest improvement, the stock could face disappointment.
Key entities
- CompanyMirum Pharmaceuticals
Developer of brelovitug and maralixibat for rare liver diseases.
- ExecutiveChris Peetz
CEO of Mirum, quoted on data significance.
